Adagio Medical Holdings, Inc. (ADGM) is a Laguna Hills, California-based medical device developer of ultra-low-temperature cryoablation catheters used to treat ventricular tachycardia and other cardiac arrhythmias. Its vCLAS system is under FDA review, supported by the 209-patient FULCRUM-VT pivotal trial. The stock was trading at $1.46 in the current session, down $0.15, or 9.32%, from the prior close of $1.61. The direction is unambiguously negative, and the decline follows the company's third-quarter report, which disclosed no revenue, a substantial-doubt going-concern qualification, and a cash position that funds operations only into early 2027.
The dominant driver is the quarterly filing published on November 16. Adagio reported no revenue for the quarter after pausing European commercial activity to concentrate resources on its U.S. pivotal program. Cash and equivalents fell to $3.1 million at September 30 from $17.1 million at the end of 2025, and management stated that existing resources should fund operations only into the first quarter of 2027. The filing carries explicit substantial doubt about the company's ability to continue as a going concern. Headcount has been cut to 18 full-time employees from 43 in September. Reported net income of $17.8 million was driven by a non-cash fair-value gain on convertible notes, not operations, and the loss per share of $5.13, while better than consensus, does little to change a liquidity picture that has driven the stock down more than 90% over the past year.
Days after completing a 1-for-30 consolidation on November 6, the company filed a proxy seeking stockholder approval for an additional reverse split of up to 1-for-1,000. For investors, the request signals that management expects continued listing pressure rather than a durable fix. The 13% senior secured convertible notes compound the problem: their floating conversion formula grants noteholders more shares per dollar as the price falls, so each leg lower mechanically expands the share count and caps rebounds. That structure explains why rallies in this name since September have been brief and why the stock has made a sequence of lower highs.
Adagio faces a December 2026 deadline to regain compliance with Nasdaq's minimum bid price rule, and it has received an extension to February 9, 2027, to satisfy the $2.5 million stockholders' equity requirement, after reporting negative equity earlier this year. These are administrative deadlines rather than operating events, but at a market value of roughly $1.5 million they dominate the equity narrative and keep the shares exposed to forced-selling dynamics ahead of each date.
Volume has been heavy relative to the post-split norm, with the prior session's turnover many times the typical daily total for the consolidated shares, and follow-through selling has continued on the current tape. The float is tiny — a few hundred thousand shares — so modest order flow produces outsized percentage moves and wide bid-ask spreads. The decline is idiosyncratic: no sector-wide catalyst or index-level event accounts for a 9% drawdown in a company this size. Technically, the shares printed a new 52-week and all-time low of $1.46, well beneath both their 50-day and 200-day moving averages, with momentum deeply oversold. There is no nearby support reference above the current level, and the nearest resistance sits at the $1.61 prior close.
The score runs from 0 — no meaningful news and an ordinary move for the stock — to 100, reserved for transformative news paired with a rare, extreme price move. Adagio scores 36 out of 100. The verified news is genuinely material for a company of this size: a quarter with no revenue, a going-concern qualification, and a request for a second reverse split within weeks. The price response, however, was not unusual by this stock's own standards. Today's 9.32% decline is roughly 1.4 times the stock's average absolute daily move of about 6.7% over the past 60-plus sessions, and eleven sessions in that window produced equal or larger swings. Strong news, routine volatility for the name — a mid-range score.
The company has scheduled a third-quarter conference call for November 18, when management is expected to address cash runway, cost structure, and the status of the strategic alternatives review launched in September. Investors will also track the FDA's review of the vCLAS premarket approval application, which remains the core asset, along with enrollment in the vCLAS Ultra IDE sub-study. Analyst coverage is sparse and targets are stale relative to the current share price. The principal risks are an equity or convertible financing at a steep discount, a failure to satisfy Nasdaq's bid price or equity requirements, and the absence of a strategic transaction, while a credible sale, partnership, or approval decision would materially change the outlook.
Tickeron's Trending AI Robots page highlights the automated strategies currently performing best under prevailing market conditions. Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers earn a place in this curated section. Bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the page offers a practical way to compare live approaches side by side. Reviewing the trending list is a straightforward next step for traders who want to see which strategies are working right now.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ADGM declined for three days, in 140 of 149 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ADGM as a result. In 35 of 39 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ADGM entered a downward trend on November 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where ADGM advanced for three days, in 77 of 91 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
ADGM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-3.473) is normal, around the industry mean (4.142). P/E Ratio (-0.047) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (60.976) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. ADGM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADGM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry MedicalNursingServices